Bioabsorbable coating with tunable hydrophobicity

Patent metadata

Field	Value
Publication number	US-8961589-B2
Application number	US-88880707-A
Country	US
Kind code	B2
Filing date	Aug 1, 2007
Priority date	Aug 1, 2007
Publication date	Feb 24, 2015
Grant date	Feb 24, 2015

Abstract

The present invention relates to implantable medical devices coated with polymer having tunable hydrophobicity and their use in the treatment of vascular diseases.

First claim

What is claimed:

1. An implantable medical device, comprising:
a device body;
an optional primer layer disposed over the device body;
a drug reservoir layer disposed over the device body or the primer layer, if opted,
wherein the drug reservoir layer comprises a polymer and a therapeutic agent and further wherein the hydrophobicity of the polymer is matched to that of the therapeutic agent so that the therapeutic agent is miscible with the polymer;
wherein the polymer is
poly(L-lactide-co-ε-caprolactone) wherein the molar ratio of L-lactide and ε-caprolactone is from 70:30 to 50:50, or
poly(L-lactide-co-trimethylene carbonate) wherein the molar ratio of L-lactide and trimethylene carbonate is 70:30;

wherein the therapeutic agent is everolimus.

2. The implantable medical device of claim 1 , wherein the poly(L-lactide-co-ε-caprolactone) has an average molecular weight from about 50,000 to about 500,000 Daltons.

3. The implantable medical device of claim 1 , wherein the drug reservoir layer has a coating thickness from 1 μm to 10 μm.

4. The implantable medical device of claim 1 , wherein the therapeutic agent to polymer wt/wt ratio is from 1.0:0.5 to 1.0:10.0.

5. The implantable medical device of claim 1 , wherein the therapeutic agent dose is from 5-200 microgram/cm 2 to 20-100 microgram/cm 2 .

6. The implantable medical device of claim 1 , wherein the device is a stent.

7. A method of treating a vascular disease, wherein the vascular disease is selected from the group consisting of atherosclerosis, restenosis, vulnerable plaque, peripheral vascular disease, and late stent thrombosis, wherein the method of treating comprises: deploying in the vasculature of a patient in need thereof an implantable medical device of claim 1 .

Assignees

• Kleiner Lothar W
• Stankus John
• Pham Nam D
• Ngo Michael H
• Maslanka Bozena Zofia
• Hossainy Syed Faiyaz Ahmed
• Trollsas Mikael
• Tang Yiwen
• Abbott Cardiovascular Systems

Inventors

• Kleiner Lothar W
• Stankus John
• Pham Nam D
• Ngo Michael H
• Maslanka Bozena Zofia
• Hossainy Syed Faiyaz Ahmed
• Trollsas Mikael
• Tang Yiwen

Classifications

• A61P37/06

  Immunosuppressants, e.g. drugs for graft rejection · CPC title

• A61L2300/416

  Anti-neoplastic or anti-proliferative or anti-restenosis or anti-angiogenic agents, e.g. paclitaxel, sirolimus · CPC title

• A61L31/16 Primary

  Biologically active materials, e.g. therapeutic substances {(A61L31/047 takes precedence)} · CPC title

• A61L31/148

  Materials at least partially resorbable by the body · CPC title

• A61K47/34

  Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers (A61K47/10 takes precedence) · CPC title